

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 53606

Title: Liver-related effects of chronic hepatitis C antiviral treatment

Reviewer's code: 02441021

Position: Editorial Board

Academic degree: MD

Professional title: Professor

Reviewer's Country/Territory: Egypt

Author's Country/Territory: Denmark

Manuscript submission date: 2020-01-31

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-01-31 18:42

Reviewer performed review: 2020-02-05 06:49

Review time: 4 Days and 12 Hours

Scientific quality	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

SPECIFIC COMMENTS TO AUTHORS

A very good review article. • Abstract -Five years ago.....No, more than 5 (The first generation DAAs are since 2011) • Hepatitis C -Hepatitis C virus (HCV) was isolated and named in 1989 [1], and in 2015, more than 70 million peopleno, 170 million people • Complications of CHC infection - Portal hypertension may be assessed by liver vein (catherization),.....what is liver vein??? Plus spelling mistake (catheterization)

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 53606

Title: Liver-related effects of chronic hepatitis C antiviral treatment

Reviewer's code: 00006518

Position: Peer Reviewer

Academic degree: MD, MHSc, PhD

Professional title: Doctor, Assistant Professor, Staff Physician

Reviewer's Country/Territory: Taiwan

Author's Country/Territory: Denmark

Manuscript submission date: 2020-01-31

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-02-05 00:35

Reviewer performed review: 2020-02-13 02:49

Review time: 8 Days and 2 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

1. Can you briefly address the progress of current studies or its limitations on liver inflammation, fibrosis, and metabolic liver function secular changes after DAA treatment for CHC patients with advanced liver disease (i.e. METAVIR fibrosis stage 3 or higher before antiviral therapy)? 2. Explain the potential differences in liver function or fibrosis changes between patients who failed to IFN or DAA treatments because of the different action mechanisms of both drugs.